This document is scheduled to be published in the Federal Register on 05/09/2018 and available online at https://federalregister.gov/d/2018-09900, and on FDsys.gov

Billing Code: 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

**National Institutes of Health** 

**National Institute on Drug Abuse; Notice of Closed Meetings** 

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby

given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections

552b(c)(4) and 552b(c)(6), Title 5 USC, as amended. The grant applications and the discussions

could disclose confidential trade secrets or commercial property such as patentable material, and

personal information concerning individuals associated with the grant applications, the

disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute on Drug Abuse Special Emphasis Panel

Identification of Biomarkers of HIV-1 Pathogenesis and Substance Abuse

Comorbidity (R01- Clinical Trials Not Allowed)

Date: June 6, 2018

Time: 12:00 PM to 3:30 PM

Agenda: To review and evaluate grant applications

Place: National Institutes of Health

Neuroscience Center

6001 Executive Boulevard

Rockville, MD 20852

(Telephone Conference Call)

1

Contact Person: Hiromi Ono, Ph.D.

Scientific Review Officer

Office of Extramural Policy and Review

National Institute on Drug Abuse National Institutes of Health, DHHS

6001 Executive Boulevard, Room 4238, MSC 9550

Bethesda, MD 20892

301-827-5820

hiromi.ono@nih.gov

Name of Committee: National Institute on Drug Abuse Special Emphasis Panel

Improving Implementation of Seek, Test, Treat & Retain Strategies among

People Who Inject Drugs in Low to Middle Income Countries

(R01-Clinical Trial Required)

Date: June 14, 2018

Time: 12:00 PM to 2:30 PM

Agenda: To review and evaluate grant applications

Place: National Institutes of Health

Neuroscience Center

6001 Executive Boulevard Rockville, MD 20852

(Telephone Conference Call)

Contact Person: Hiromi Ono, Ph.D.

Scientific Review Officer

Office of Extramural Policy and Review

National Institute on Drug Abuse National Institutes of Health, DHHS

6001 Executive Boulevard, Room 4238, MSC 9550

Bethesda, MD 20892

301-827-5820

hiromi.ono@nih.gov

Name of Committee: National Institute on Drug Abuse Special Emphasis Panel

Identification of Genetic and Genomic Variants by Next-Gen Sequencing

in Non-Human Animal Models (U01)

Date: June 21, 2018

Time: 12:00 PM to 2:00 PM

Agenda: To review and evaluate cooperative agreement applications

Place: National Institutes of Health

Neuroscience Center

6001 Executive Boulevard Rockville, MD 20852

(Telephone Conference Call)

Contact Person: Gerald L. McLaughlin, Ph.D.

Scientific Review Officer

Office of Extramural Policy and Review

National Institute on Drug Abuse, NIH, DHHS 6001 Executive Blvd., Room 4238, MSC 9550

Bethesda, MD 20892-9550

301-827-5819 gm145a@nih.gov

(Catalogue of Federal Domestic Assistance Program Nos.: 93.279, Drug Abuse and Addiction Research Programs, National Institutes of Health, HHS)

Dated: May 4, 2018. **Natasha M. Copeland,** 

Program Analyst,

Office of Federal Advisory Committee Policy.

[FR Doc. 2018-09900 Filed: 5/8/2018 8:45 am; Publication Date: 5/9/2018]